Related Experiment Video
Updated: Sep 17, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Outpatient interface challenges for drug safety in Parkinson's disease patients: a questionnaire based
Stephan Greten1, Clara Niesmann1, Lea Krey1
1Department of Neurology, Hannover Medical School, Hannover, Germany.
Background:
Parkinson's disease (PD) is a chronic and multifaceted disease with a variety of motor and non-motor symptoms. The safe symptomatic drug therapy of often multimorbid patients places enormous demands on the competence, communication and coordination of the treating physicians, particularly in the outpatient sector.
Objectives:
This study aimed to explore aspects of drug safety and interdisciplinary communication in the outpatient sector of PD patients.
Methods:
A semistructured questionnaire was designed addressing various aspects of drug safety in the outpatient setting. The questionnaire was sent to a total of 1,002 general practitioners (GP) and 1,005 neurologists (NEU).
Results:
One hundred and forty-seven NEU and eighty-four GP answered the questionnaire. Overall, NEU treated more PD patients, while GP cared for more geriatric PD patients, especially outside of the outpatient clinic (home visits, nursing homes). Regarding the execution of recommended laboratory or technical check-ups, as well as the prescription of new medications, neither a formal agreement nor structured communication existed. Merely the identification of potential drug-drug interactions (DDI) was regularly carried out by both professions.
Conclusion:
The inadequate interdisciplinary communication hampers therapy safety and consequently the safety of the vulnerable PD patient group. For this reason, standardized and comprehensive communication mechanisms are urgently needed. Solution approaches may include an individual protected digital health record or integrated treatment networks comprising all professionals participating in the management of PD patients.
More Related Videos
06:45Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
08:36The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
Published on: July 28, 2022
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Therapy
Antianxiety Medications
Factors Affecting Drug Response: Overview
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...